ES2816050T3 - Derivado heteroarilo o sal farmacéuticamente aceptable del mismo, método de preparación del mismo y composición farmacéutica para prevenir o tratar enfermedades asociadas con PI3 quinasas, que contiene el mismo como principio activo - Google Patents
Derivado heteroarilo o sal farmacéuticamente aceptable del mismo, método de preparación del mismo y composición farmacéutica para prevenir o tratar enfermedades asociadas con PI3 quinasas, que contiene el mismo como principio activo Download PDFInfo
- Publication number
- ES2816050T3 ES2816050T3 ES16811842T ES16811842T ES2816050T3 ES 2816050 T3 ES2816050 T3 ES 2816050T3 ES 16811842 T ES16811842 T ES 16811842T ES 16811842 T ES16811842 T ES 16811842T ES 2816050 T3 ES2816050 T3 ES 2816050T3
- Authority
- ES
- Spain
- Prior art keywords
- amino
- oxo
- pyrimidin
- ethyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *CC(*)N(*)c1nc(I)nc(N[C@@]2*3(*)C2)c1C3=O Chemical compound *CC(*)N(*)c1nc(I)nc(N[C@@]2*3(*)C2)c1C3=O 0.000 description 16
- ITQGSDBDMFFTGT-WNTQMRJWSA-N C=CC(C1C(Cl)=C)C=C([C@H]2NCCC2)N(/C=C/C=C\C=C)C1=O Chemical compound C=CC(C1C(Cl)=C)C=C([C@H]2NCCC2)N(/C=C/C=C\C=C)C1=O ITQGSDBDMFFTGT-WNTQMRJWSA-N 0.000 description 1
- AMSDNLPXLRBNDB-UHFFFAOYSA-N CC(C(N(C(C12)=O)c3cnccc3)=NC1C=CC=C2Cl)NC1=NCNC(NCN2C)=C1C2=O Chemical compound CC(C(N(C(C12)=O)c3cnccc3)=NC1C=CC=C2Cl)NC1=NCNC(NCN2C)=C1C2=O AMSDNLPXLRBNDB-UHFFFAOYSA-N 0.000 description 1
- KECBNUDELGGALQ-ISTTXYCBSA-N CC(C(N1C(/C=C\C=C/C)=C)=Nc(ccc(F)c2)c2C1=O)Nc1[n]cnc(N(Cc(cc2)ccc2OC)C=C2)c1C2O Chemical compound CC(C(N1C(/C=C\C=C/C)=C)=Nc(ccc(F)c2)c2C1=O)Nc1[n]cnc(N(Cc(cc2)ccc2OC)C=C2)c1C2O KECBNUDELGGALQ-ISTTXYCBSA-N 0.000 description 1
- GHRFHEKSYPGUJD-BGERDNNASA-N CC(C([C@H]1C)=Nc(ccc(F)c2)c2C=C1c1ncccc1)Nc1ncnc(N(Cc(cc2)ccc2OC)C=C2)c1C2=O Chemical compound CC(C([C@H]1C)=Nc(ccc(F)c2)c2C=C1c1ncccc1)Nc1ncnc(N(Cc(cc2)ccc2OC)C=C2)c1C2=O GHRFHEKSYPGUJD-BGERDNNASA-N 0.000 description 1
- WDOGJHZCWHPBCS-UHFFFAOYSA-N CC(C)N(CNc1c2c(NC(C)C(N3c4ccccc4)=Cc(cccc4C)c4C3=O)ncn1)C2=O Chemical compound CC(C)N(CNc1c2c(NC(C)C(N3c4ccccc4)=Cc(cccc4C)c4C3=O)ncn1)C2=O WDOGJHZCWHPBCS-UHFFFAOYSA-N 0.000 description 1
- VDWPJMAVBIDZDA-WZONPJLNSA-N CC(CC=C1)C=C1N(C(C1NCCC1)=NC([C@@]12C)C=CC=C1Cl)C2=O Chemical compound CC(CC=C1)C=C1N(C(C1NCCC1)=NC([C@@]12C)C=CC=C1Cl)C2=O VDWPJMAVBIDZDA-WZONPJLNSA-N 0.000 description 1
- KJQKTRRADWXSJI-UHFFFAOYSA-N CCC(C(N1c2ccccc2)=Nc(cccc2F)c2C1=O)Nc1ncnc(NC=N2)c1C2=O Chemical compound CCC(C(N1c2ccccc2)=Nc(cccc2F)c2C1=O)Nc1ncnc(NC=N2)c1C2=O KJQKTRRADWXSJI-UHFFFAOYSA-N 0.000 description 1
- ZZPNVXBMVMQCQN-GKEIQFAZSA-N CC[C@@H](C(N1C2=C[C@@H](C)CC=C2)=Nc2cccc(F)c2C1O)N Chemical compound CC[C@@H](C(N1C2=C[C@@H](C)CC=C2)=Nc2cccc(F)c2C1O)N ZZPNVXBMVMQCQN-GKEIQFAZSA-N 0.000 description 1
- QWCKQJZIFLGMSD-VKHMYHEASA-N CC[C@@H](C(O)=O)N Chemical compound CC[C@@H](C(O)=O)N QWCKQJZIFLGMSD-VKHMYHEASA-N 0.000 description 1
- PNFVIPIQXAIUAY-LURJTMIESA-N CC[C@@H](C(O)=O)NC(OC(C)(C)C)=O Chemical compound CC[C@@H](C(O)=O)NC(OC(C)(C)C)=O PNFVIPIQXAIUAY-LURJTMIESA-N 0.000 description 1
- JUFROVQEZBBAHE-NTFOPCPOSA-O CN(CN(C)N[C@H]1/C(/N)=[NH+]\C(N)SC)C1=O Chemical compound CN(CN(C)N[C@H]1/C(/N)=[NH+]\C(N)SC)C1=O JUFROVQEZBBAHE-NTFOPCPOSA-O 0.000 description 1
- IQCYPBSKVPOXOJ-UHFFFAOYSA-N CN(CNc1c2c(N(CCC3)C3C(N3c4cnccc4)=Nc4cccc(Cl)c4C3=O)ncn1)C2=O Chemical compound CN(CNc1c2c(N(CCC3)C3C(N3c4cnccc4)=Nc4cccc(Cl)c4C3=O)ncn1)C2=O IQCYPBSKVPOXOJ-UHFFFAOYSA-N 0.000 description 1
- RGYCDUMWEVRFGZ-UHFFFAOYSA-N COc1ccc(CN(C=CC2=O)c3c2c(O)ncn3)cc1 Chemical compound COc1ccc(CN(C=CC2=O)c3c2c(O)ncn3)cc1 RGYCDUMWEVRFGZ-UHFFFAOYSA-N 0.000 description 1
- NFUZOSPPGQHAQZ-WHGJXMNKSA-N C[C@@H](/C=N/c1cccc(Cl)c1C(Nc1cnccc1)=O)N Chemical compound C[C@@H](/C=N/c1cccc(Cl)c1C(Nc1cnccc1)=O)N NFUZOSPPGQHAQZ-WHGJXMNKSA-N 0.000 description 1
- MZINZXIFJMLTOK-NSHDSACASA-N C[C@@H](C(N1c2ccccc2)=Cc(cccc2Cl)c2C1=O)N Chemical compound C[C@@H](C(N1c2ccccc2)=Cc(cccc2Cl)c2C1=O)N MZINZXIFJMLTOK-NSHDSACASA-N 0.000 description 1
- MJEQBVILBMIIKK-MYHCZTBNSA-N C[C@@H](C(Nc(cc1)c2cc1F)N(c1ccccc1)C2=O)N Chemical compound C[C@@H](C(Nc(cc1)c2cc1F)N(c1ccccc1)C2=O)N MJEQBVILBMIIKK-MYHCZTBNSA-N 0.000 description 1
- ZBSJAJVMTBBBGX-JGINKSFDSA-N C[C@@H](c(nc(ccc(F)c1)c1c1)c1/C(/N=C\I)=C/C)Nc1ncncc1C(/C=C\NC)=O Chemical compound C[C@@H](c(nc(ccc(F)c1)c1c1)c1/C(/N=C\I)=C/C)Nc1ncncc1C(/C=C\NC)=O ZBSJAJVMTBBBGX-JGINKSFDSA-N 0.000 description 1
- ZIIBNILTPUKKPJ-SDKNWNMFSA-N C[C@H]([C@@H]1C=O)NC(N)N=C1N Chemical compound C[C@H]([C@@H]1C=O)NC(N)N=C1N ZIIBNILTPUKKPJ-SDKNWNMFSA-N 0.000 description 1
- ZCAYCVWSMBGSQM-SFHVURJKSA-N Cc1cccc(N(C([C@H](CCC2)N2c2ncnc(NC=N3)c2C3=O)=Nc2cccc(Cl)c22)C2=O)c1 Chemical compound Cc1cccc(N(C([C@H](CCC2)N2c2ncnc(NC=N3)c2C3=O)=Nc2cccc(Cl)c22)C2=O)c1 ZCAYCVWSMBGSQM-SFHVURJKSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N Cc1ccccn1 Chemical compound Cc1ccccn1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- ZJCLIHWKCSSABD-AWEZNQCLSA-N O=C(c(c(Cl)ccc1)c1N=C1[C@H]2NCCC2)N1c1cnccc1 Chemical compound O=C(c(c(Cl)ccc1)c1N=C1[C@H]2NCCC2)N1c1cnccc1 ZJCLIHWKCSSABD-AWEZNQCLSA-N 0.000 description 1
- FXUNYBWENWDAQA-UHFFFAOYSA-N O=C1N=CNc2c1c(Cl)ncn2 Chemical compound O=C1N=CNc2c1c(Cl)ncn2 FXUNYBWENWDAQA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150086372 | 2015-06-18 | ||
| KR1020160067210A KR101845931B1 (ko) | 2015-06-18 | 2016-05-31 | 헤테로아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
| PCT/KR2016/005798 WO2016204429A1 (ko) | 2015-06-18 | 2016-06-01 | 헤테로아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2816050T3 true ES2816050T3 (es) | 2021-03-31 |
Family
ID=57724790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16811842T Active ES2816050T3 (es) | 2015-06-18 | 2016-06-01 | Derivado heteroarilo o sal farmacéuticamente aceptable del mismo, método de preparación del mismo y composición farmacéutica para prevenir o tratar enfermedades asociadas con PI3 quinasas, que contiene el mismo como principio activo |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10526337B2 (enExample) |
| EP (1) | EP3312175B1 (enExample) |
| JP (1) | JP6808905B2 (enExample) |
| KR (1) | KR101845931B1 (enExample) |
| CN (1) | CN107690433B (enExample) |
| AU (1) | AU2016279661B2 (enExample) |
| CA (1) | CA2979815C (enExample) |
| ES (1) | ES2816050T3 (enExample) |
| HU (1) | HUE052332T2 (enExample) |
| MX (1) | MX385704B (enExample) |
| MY (1) | MY189345A (enExample) |
| PH (1) | PH12017501989B1 (enExample) |
| PL (1) | PL3312175T3 (enExample) |
| PT (1) | PT3312175T (enExample) |
| RU (1) | RU2719367C2 (enExample) |
| SG (1) | SG11201707448SA (enExample) |
| TW (1) | TWI616446B (enExample) |
| ZA (1) | ZA201707096B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200055116A (ko) * | 2018-01-10 | 2020-05-20 | 보령제약 주식회사 | Pi3 키나아제 억제제 및 면역관문 억제제를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| WO2019139399A1 (ko) * | 2018-01-12 | 2019-07-18 | 보령제약 주식회사 | Pi3 키나아제 억제제 및 세포독성 항암제를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| EP3740468B1 (en) | 2018-01-20 | 2025-12-31 | Sunshine Lake Pharma Co., Ltd. | Substituted Aminopyrimidine Compounds and Methods of Use |
| CN111018834B (zh) * | 2018-10-10 | 2022-07-15 | 成都理工大学 | 作为PPAR-γ调节剂的氨基嘧啶丁烯酮衍生物 |
| KR20200129704A (ko) * | 2019-05-09 | 2020-11-18 | 보령제약 주식회사 | Pi3k 저해제의 결정다형 및 이의 제조방법 |
| KR20200129705A (ko) * | 2019-05-09 | 2020-11-18 | 보령제약 주식회사 | 무정형의 pi3k 저해제 및 이를 포함하는 약학적 조성물 |
| KR102338609B1 (ko) * | 2019-05-20 | 2021-12-14 | 보령제약 주식회사 | 피리도-피리미딘 화합물 및 이를 유효성분으로 포함하는 pi3k 관련 질환의 예방 또는 치료용 약학적 조성물 |
| CN112194659A (zh) | 2019-07-08 | 2021-01-08 | 浙江海正药业股份有限公司 | 炔类衍生物及其制备方法和用途 |
| KR20210115375A (ko) * | 2020-03-12 | 2021-09-27 | 보령제약 주식회사 | Pi3 키나아제 저해제 및 btk 저해제를 포함하는 조성물 |
| WO2021201574A1 (ko) * | 2020-03-31 | 2021-10-07 | 보령제약 주식회사 | Pi3k 저해제로서의 화합물의 제조방법 및 이의 제조를 위한 중간체 화합물 |
| CN118373824A (zh) * | 2020-04-09 | 2024-07-23 | 成都赜灵生物医药科技有限公司 | 取代喹唑啉-4-酮类化合物及其制备方法和用途 |
| CN113527231A (zh) * | 2020-04-15 | 2021-10-22 | 深圳华大生命科学研究院 | 杂环取代腔肠素类化合物的合成方法 |
| WO2022005175A1 (ko) * | 2020-06-30 | 2022-01-06 | 보령제약 주식회사 | Pi3k 저해제로서의 화합물의 제조방법 및 이의 제조를 위한 중간체 화합물 |
| CN118201617A (zh) * | 2021-11-03 | 2024-06-14 | 株式会社保宁 | 包含pi3k及dna-pk双重抑制剂的外周t细胞淋巴瘤的预防或治疗用组合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1277738A (en) | 1916-04-03 | 1918-09-03 | American Can Co | Sardine-can. |
| AU5261001A (en) | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd | Condensed heteroaryl derivatives |
| DK2316831T3 (da) | 2002-11-21 | 2013-06-10 | Novartis Ag | 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer |
| UA81790C2 (uk) * | 2002-12-19 | 2008-02-11 | Фармация Италия С.П.А. | Заміщені піролопіразольні похідні як інгібітори кінази |
| TW200942537A (en) * | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| CA2781865A1 (en) | 2009-06-25 | 2010-12-29 | Amgen Inc. | Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases |
| JP5993742B2 (ja) * | 2009-10-29 | 2016-09-14 | ジェノスコ | キナーゼ阻害剤 |
| WO2014015523A1 (en) | 2012-07-27 | 2014-01-30 | Hutchison Medipharma Limited | Novel heteroaryl and heterocycle compounds, compositions and methods |
| GB201306610D0 (en) | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
| CN104151311B (zh) * | 2014-01-13 | 2017-01-04 | 华中师范大学 | 一类稠环化合物或其药学上可接受的盐及其制备方法和应用 |
-
2016
- 2016-05-31 KR KR1020160067210A patent/KR101845931B1/ko active Active
- 2016-06-01 CN CN201680030953.XA patent/CN107690433B/zh active Active
- 2016-06-01 JP JP2017565779A patent/JP6808905B2/ja active Active
- 2016-06-01 PH PH1/2017/501989A patent/PH12017501989B1/en unknown
- 2016-06-01 HU HUE16811842A patent/HUE052332T2/hu unknown
- 2016-06-01 US US15/567,692 patent/US10526337B2/en active Active
- 2016-06-01 RU RU2017140446A patent/RU2719367C2/ru active
- 2016-06-01 SG SG11201707448SA patent/SG11201707448SA/en unknown
- 2016-06-01 MX MX2017014478A patent/MX385704B/es unknown
- 2016-06-01 PL PL16811842T patent/PL3312175T3/pl unknown
- 2016-06-01 ES ES16811842T patent/ES2816050T3/es active Active
- 2016-06-01 AU AU2016279661A patent/AU2016279661B2/en active Active
- 2016-06-01 EP EP16811842.0A patent/EP3312175B1/en active Active
- 2016-06-01 CA CA2979815A patent/CA2979815C/en active Active
- 2016-06-01 PT PT168118420T patent/PT3312175T/pt unknown
- 2016-06-01 MY MYPI2017001544A patent/MY189345A/en unknown
- 2016-06-15 TW TW105118848A patent/TWI616446B/zh active
-
2017
- 2017-10-19 ZA ZA2017/07096A patent/ZA201707096B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201707096B (en) | 2018-11-28 |
| TW201712010A (zh) | 2017-04-01 |
| MY189345A (en) | 2022-02-05 |
| RU2719367C2 (ru) | 2020-04-17 |
| RU2017140446A3 (enExample) | 2019-10-29 |
| PT3312175T (pt) | 2020-09-29 |
| MX385704B (es) | 2025-03-18 |
| SG11201707448SA (en) | 2017-10-30 |
| JP6808905B2 (ja) | 2021-01-06 |
| HUE052332T2 (hu) | 2021-04-28 |
| KR101845931B1 (ko) | 2018-04-05 |
| EP3312175B1 (en) | 2020-07-22 |
| US20180105527A1 (en) | 2018-04-19 |
| CA2979815A1 (en) | 2016-12-22 |
| KR20160150006A (ko) | 2016-12-28 |
| AU2016279661B2 (en) | 2020-05-07 |
| MX2017014478A (es) | 2018-03-01 |
| US10526337B2 (en) | 2020-01-07 |
| EP3312175A1 (en) | 2018-04-25 |
| CA2979815C (en) | 2023-10-24 |
| EP3312175A4 (en) | 2018-12-12 |
| BR112017025518A2 (pt) | 2018-08-07 |
| TWI616446B (zh) | 2018-03-01 |
| AU2016279661A1 (en) | 2017-09-14 |
| RU2017140446A (ru) | 2019-05-21 |
| HK1250714A1 (zh) | 2019-01-11 |
| PH12017501989B1 (en) | 2024-01-17 |
| PL3312175T3 (pl) | 2021-01-11 |
| PH12017501989A1 (en) | 2018-03-26 |
| CN107690433B (zh) | 2021-04-09 |
| CN107690433A (zh) | 2018-02-13 |
| JP2018522852A (ja) | 2018-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016279661B2 (en) | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with PI3 kinases, containing same as active ingredient | |
| EP3524603B1 (en) | Fgfr4 inhibitor, preparation method therefor and pharmaceutical use thereof | |
| CA2684693C (en) | 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer | |
| US10793575B2 (en) | Oxoisoquinoline derivatives | |
| JP2021502383A (ja) | Ｓｔｉｎｇ調節剤化合物、ならびに製造及び使用する方法 | |
| CN107108644A (zh) | 二氟甲基‑氨基吡啶和二氟甲基‑氨基嘧啶 | |
| WO2016204429A1 (ko) | 헤테로아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물. | |
| KR20130116358A (ko) | Pi3 키나아제 억제제로서 헤테로사이클릭 화합물 | |
| US20240383905A1 (en) | Fgfr inhibitors and methods of use thereof | |
| WO2014106800A2 (en) | Substituted 2-amino pyrimidine derivatives as kinase inhibitors | |
| KR101767260B1 (ko) | 피리미도 옥사진 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| BR112017025518B1 (pt) | Compostos derivado de heteroarila, isômero óptico do mesmo ou sal farmaceuticamente aceitável do mesmo, uso dos mesmos e composição farmacêutica para a prevenção ou tratamento de doença relacionada à pi3 quinase, bem como métodos para preparar os ditos compostos | |
| KR101796779B1 (ko) | 다이하이드로프테리딘-온 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| HK1250714B (en) | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient | |
| AU2016302302A1 (en) | Pyrrolo[2,3-d]pyrimidine compound or salt thereof | |
| HK1142067A (en) | 9-(pyraxzol-3-yl)-9h-purine-2-amine and 3-(pyrazol-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer | |
| JP2022533700A (ja) | ピリド－ピリミジン誘導体、およびそれを有効成分として含有するｐｉ３ｋ関連疾患の予防または治療用の医薬組成物 |